To provide the information your oncologist is not telling you or doesn't have the time to!
Explore a comprehensive range of insights and information within our ‘Varied Cancer Perspectives’ category. From melanoma to breast cancer, colorectal cancer to sarcoma, and beyond, this diverse collection delves into the multifaceted world of oncology. Gain a nuanced understanding of different cancer types, treatments, and the latest advancements in research. Whether you’re seeking knowledge on pediatric oncology, uveal melanoma, or desmoid tumors, our curated content provides a holistic view, offering valuable perspectives to empower and inform those navigating the complexities of cancer care. Join us on a journey through varied perspectives, ensuring a well-rounded understanding of the ever-evolving landscape of cancer.
Living with Sickle Cell Living with sickle cell disease (SCD) presents unique challenges, both in the short term and over a lifetime. As a chronic illness that primarily affects the shape and function of red blood cells, SCD leads to a variety of complications, from pain crises to organ damage, all of which can have …
Gene Therapy: A Promising Future As I continue to highlight key aspects of SCD this September, I will shift the focus to the exciting advancements in research and treatment. Recent breakthroughs offer new hope and possibilities for individuals living with this condition. In this installment, we’ll explore the latest research developments, including innovative therapies and …
Sickle Cell Disease Treatment Options In the previous post, I explored the fundamental aspects of SCD, from its genetic basis to the everyday challenges faced by those living with this condition. As I continue this journey, I will dive deeper into the current treatment options available for managing SCD and how these approaches can improve …
Sickle Cell Disease Awareness September is Sickle Cell Awareness Month, a time dedicated to shedding light on a condition that affects millions worldwide, including more than 100,000 people in the United States alone—90% of whom are African American. People with sickle cell disease face significant health challenges, with a life expectancy that is, on average, …
A recent article published in the New England Journal of Medicine (NEJM) demonstrated higher response, longer progression free survival and overall survival in patients with unresectable or metastatic leiomyosarcoma. A treatment protocol that we’ve been doing for at least 1-2 years prior given the known higher response rate reported at conferences. This is a new …
EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) EGFR (epidermal growth factor receptor) is a protein located on the surface of cells that regulates their growth and division. Mutations in the EGFR gene can lead to uncontrolled cell growth and are commonly found in various cancers, including non-small cell lung cancer (NSCLC). In patients with unresectable stage …
Stage III melanoma means the cancer has spread beyond the original tumor to nearby areas but hasn’t reached distant parts of the body. The prognosis for Stage III melanoma varies depending on several factors, including the extent of lymph node involvement, the presence of in-transit or satellite lesions, and the patient’s overall health. Treatment for …
Multiple myeloma (MM) is a type of blood cancer that originates in the plasma cells, which are a type of white blood cell found in the bone marrow. Plasma cells are responsible for producing antibodies that help fight infections. In multiple myeloma, abnormal plasma cells multiply uncontrollably, leading to a range of complications. Key Characteristics …
When it comes to battling a rare and aggressive cancer like synovial sarcoma, the treatment options have often been limited—until now. The FDA’s recent approval of Tecelra (Amafi-Cel), the first gene therapy for adults with metastatic synovial sarcoma, not only provides new hope for patients who’ve exhausted other options but also paves the way for …
Esophageal adenocarcinoma (EAC) is a malignancy with rising incidence in Western countries, largely due to increasing rates of gastroesophageal reflux disease and obesity. Despite advancements in treatment, the prognosis for EAC remains poor, with a five-year survival rate of less than 20% for advanced stages. Current management of locally advanced, resectable EAC often involves neoadjuvant …